Efficacy and safety of iodine-125 seed implantations combined with chemotherapy and immunotherapy for patients with non-small cell lung cancer: protocol for a systematic review and meta-analysis

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e094632 - e094632

Published: April 1, 2025

Background Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide, with conventional treatments often limited by radiation resistance, systemic toxicity and poor outcomes in advanced stages. Iodine-125 (I-125) seed implantation, combined chemotherapy immunotherapy, has emerged as promising therapeutic strategy, but its efficacy safety compared external beam radiotherapy therapies remain unclear. This systematic review meta-analysis aims to synthesise the available evidence evaluate comparative benefits risks these treatment modalities. Methods analysis Two reviewers will independently search seven databases—PubMed, Embase, Web Science Cochrane Library—for randomised controlled trials (RCTs). These RCTs should compare I-125 implantations immunotherapy against chemoradiotherapy patients NSCLC. The risk bias included studies be evaluated using Revised risk-of-bias tool V.2. Data synthesis conducted RevMan software. Trial sequential applied primary outcomes. Additionally, subgroup sensitivity analyses performed assess robustness findings. Ethics dissemination Ethical approval not required because this study secondary existing data. We disseminate findings through peer-reviewed publications. PROSPERO registration number CRD42024591684.

Language: Английский

Efficacy of Durvalumab Consolidation Therapy After Sequential Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer—Experience from the Daily Hospital of Clinic for Pulmonology, University Clinical Center of Serbia

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 892 - 892

Published: April 7, 2025

Background/Objectives: Patients with stage III non-small cell lung cancer represent a very heterogeneous group of patients. In the past, standard care for patients inoperable was concurrent or sequential radical radiotherapy and chemotherapy. But progression-free survival 8 months, 5-year overall rate less than 20%. After results PACIFIC study, this is chemoradiotherapy durvalumab as consolidation therapy. The aim our study to evaluate efficacy in real-world setting after CRT. Methods: We included 24 unresectable who did not progress received consolidation. Results: Median 16 95% CI (0.5–31.5), median 20 (13.4–26.6 months). twelve-month were 55.1% 68%, respectively, 18-month rates 44.1% 56.5%, respectively. Conclusions: Durvalumab introduced new era treatment significantly prolonged rate. Our one few that investigated showed effective treated However, time between termination start should be shorter.

Language: Английский

Copper-Imidazopyridines Activate P53 and Cause Apoptosis in A549 Lung Cancer Cells

Published: Jan. 1, 2024

Language: Английский